SEARCH:   Advanced

Blood, 15 November 2006, Vol. 108, No. 10, pp. 3560-3563. Prepublished online as a Blood First Edition Paper on July 27, 2006; DOI 10.1182/blood-2006-03-010835. This Article Full Text (PDF) Supplemental Table and Figures All Versions of this Article: blood-2006-03-010835v1 108/10/3560    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Chapiro, E. Articles by Nguyen-Khac, F. Search for Related Content PubMed PubMed Citation Articles by Chapiro, E. Articles by Nguyen-Khac, F. Related Collections Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted March 21, 2006 Accepted May 22, 2006 Overexpression of CEBPA resulting from the translocation t(14;19)(q32;q13) of human precursor B acute lymphoblastic leukemia Elise Chapiro, Lisa Russell, Isabelle Radford-Weiss, Christian Bastard, Michel Lessard, Stephanie Struski, Helene Cave, Sandra Fert-Ferrer, Carole Barin, Odile Maarek, Veronique Della-Valle, Jonathan C Strefford, Roland Berger, Christine J Harrison, Olivier A Bernard, and Florence Nguyen-Khac* INSERM; APHP Service d'Hematologie Biologique, Hopital Pitie-Salpetriere Leukaemia Research Cytogenetics Group, University of Southampton, Southampton, UK INSERM; APHP Laboratoire de Cytogenetique, Hopital Necker-Enfants Malades Laboratoire de Genetique Oncologique, Rouen Laboratoire d'Hematologie, Hopital Hautepierre, Strasbourg APHP Laboratoire de Biochimie Genetique, Hopital Robert Debre Laboratoire de Genetique, Centre Hospitalier de CHAMBERY Laboratoire de Genetique, Tours, France APHP Laboratoire d'Hematologie, Hopital Saint-Louis, Paris, France INSERM, E0210, Paris France; Univ Rene Descarte, Paris, France * Corresponding author; email: florence.nguyen{at}psl.aphp.fr. Subtle variation in the expression or function of a small group of transcription factors can drive leukemogenesis. The CEBPA protein is known to regulate the balance between cell proliferation and differentiation during early hematopoietic development and myeloid differentiation. In human myeloid leukemia, CEBPA is frequently inactivated by mutation, indirect and post-translational mechanisms, in keeping with tumor suppressor properties. We report that CEBPA is activated by juxtaposition to the immunoglobulin gene enhancer upon its rearrangement with the immunoglobulin heavy chain locus in precursor B cell acute lymphoblastic leukemia harboring t(14;19)(q32;q13). Over-expression of apparently normal CEBPA RNA or protein was observed in 6 cases. These data indicate that CEBPA may exhibit oncogenic as well as tumor suppressor properties in human leukemogenesis. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: CEBPA dosage in leukemogenesis Thomas Mercher and D. Gary Gilliland Blood 2006 108: 3234. [Full Text] [PDF]

	Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020